Patología Hepática S 59 Tratamient o farmac ológic o HGNA - F. Barrera M. Elafibranor, an agonist of the peroxisome proliferator-activated receptor -alpha and- delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016; 150: 1147-59. 10.- Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679-90. 11.- Cui J, Philo L, Nguyen P, Hofflich H, Hernández C, Bettencourt R, et al. Sitagliptin vs placebo for nonalcoholic fatty liver disease: A randomized controlled trial. J Hepatol 2016; 65: 369- 76. 12.- Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2016; 43: 1109-23. 13.- Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 2015; 149: 379-88. Gastroenterol. latinoam 2016; Vol 27, S upl Nº 1: S 55-S 59
Gastro_3
To see the actual publication please follow the link above